

# Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User-Global Forecast to 2031

<https://marketpublishers.com/r/VF7A24B4FAA7EN.html>

Date: February 2026

Pages: 483

Price: US\$ 4,950.00 (Single User License)

ID: VF7A24B4FAA7EN

## Abstracts

The global veterinary pharmaceuticals market is projected to grow at a CAGR of 6.3% from 2026 to 2031, reflecting steady expansion across both companion and livestock segments. Growth is supported by rising pet humanization, increasing prevalence of chronic and infectious diseases, and higher spending on advanced therapeutics. In livestock, productivity pressures and stricter food safety standards continue to drive pharmaceutical demand, sustaining consistent mid-single-digit market growth.

**“By product type, the monoclonal antibodies segment is expected to witness the fastest growth rate during the forecast period.”**

The monoclonal antibodies segment is expected to grow fastest in the global veterinary pharmaceuticals market, supported by a growing preference for targeted and durable treatment options, especially in companion animals. The rising burden of chronic disorders, including atopic dermatitis, osteoarthritis, and immune-mediated conditions, is boosting demand. These therapies offer precise action, fewer adverse effects, and longer dosing intervals, improving compliance. Continued investment in biologics development and the expanding premium pet care market are further driving segment expansion.

**“By indication, the dermatological diseases segment has accounted for the**

### **largest share in the Veterinary pharmaceuticals market in 2025.”**

The dermatological conditions segment is projected to hold the largest share of the global veterinary pharmaceuticals market in 2025, primarily due to the widespread occurrence of skin-related disorders in both companion and livestock animals. Common conditions such as atopic dermatitis, parasitic infections, fungal diseases, and bacterial skin infections require ongoing management and medication. Growing pet adoption, heightened focus on animal hygiene, and strong demand for anti-parasitic, antifungal, and anti-inflammatory treatments continue to reinforce the segment’s dominant position.

### **“North America dominated the global veterinary pharmaceuticals market in 2025.”**

North America leads the veterinary pharmaceuticals market in 2025, supported by a mature animal healthcare ecosystem and strong purchasing power. The region records high spending on companion animal treatments and maintains a large commercial livestock base. Robust R&D investments, rapid approval pathways for innovative drugs, and the strong presence of established manufacturers further strengthen its position. Well-developed distribution networks and growing awareness of preventive animal care also contribute to its leading market position.

Breakdown of supply-side primary interviews:

By Company Type: Tier 1 – 45%, Tier 2 – 20%, and Tier 3 – 35%

By Designation: C-level – 35%, Director-level – 25%, and Others – 40%

By Region: North America - 40%, Europe – 25%, APAC – 20%, Latin America – 10%, Middle East & Africa – 5%

## **Research Coverage**

This report examines the veterinary pharmaceuticals market by product type, route of administration, formulation type, indications, animal type, distribution channel, end user, and region. It also examines factors (such as drivers, restraints, opportunities, and challenges) that affect market growth. It analyzes market opportunities and challenges and provides details on the competitive landscape for market leaders. Furthermore, the

report analyzes micro-markets by their individual growth trends and forecasts market segment revenue across five main regions and their respective countries.

### **Reasons to Buy the Report**

The report can help established firms as well as new entrants/smaller firms gauge the market pulse, which, in turn, would help them gain a greater share. Firms purchasing the report could use one or a combination of the following five strategies.

### **This report provides insights into the following pointers:**

Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the veterinary pharmaceuticals market.

**Product Development/Innovation:** Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary pharmaceuticals market.

**Market Development:** Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of catheterization procedures across regions.

**Market Diversification:** Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary pharmaceuticals market.

**Competitive Assessment:** In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary pharmaceuticals market.

## Contents

### 1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
  - 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 MARKET SCOPE
  - 1.3.1 MARKETS COVERED
  - 1.3.2 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS

### 2 EXECUTIVE SUMMARY

- 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

### 3 PREMIUM INSIGHTS

- 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY PHARMACEUTICALS MARKET
- 3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE AND COUNTRY
- 3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS. DEVELOPED ECONOMIES, 2026?2031

### 4 MARKET OVERVIEW

- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
  - 4.2.1 DRIVERS
    - 4.2.1.1 Rising companion animal ownership and pet humanization
    - 4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals

- 4.2.1.3 Increasing demand for animal-derived food products
- 4.2.2 RESTRAINTS
  - 4.2.2.1 Growing concerns over antimicrobial resistance (AMR)
  - 4.2.2.2 Stringent regulatory approval processes for veterinary drugs
- 4.2.3 OPPORTUNITIES
  - 4.2.3.1 Rising demand for parasiticides and dermatology products
  - 4.2.3.2 Growth potential in rural and low-income regions
- 4.2.4 CHALLENGES
  - 4.2.4.1 Monitoring drug residues in food-producing animals
  - 4.2.4.2 Balancing animal welfare, productivity, and compliance requirements
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES
  - 4.4.1 INTERCONNECTED MARKETS
  - 4.4.2 CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

## **5 INDUSTRY TRENDS**

- 5.1 PORTER'S FIVE FORCES ANALYSIS
  - 5.1.1 THREAT OF NEW ENTRANTS
  - 5.1.2 THREAT OF SUBSTITUTES
  - 5.1.3 BARGAINING POWER OF SUPPLIERS
  - 5.1.4 BARGAINING POWER OF BUYERS
  - 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMICS INDICATORS
  - 5.2.1 INTRODUCTION
  - 5.2.2 GDP TRENDS AND FORECAST
  - 5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY
  - 5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 SUPPLY CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 PRICING ANALYSIS
  - 5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025
  - 5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025
  - 5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025
- 5.7 TRADE ANALYSIS

- 5.7.1 IMPORT DATA FOR HS CODE 30, 2021–2024
  - 5.7.1.1 Import scenario (HS code 30)
- 5.7.2 EXPORT DATA FOR HS CODE 30, 2021–2024
- 5.7.3 EXPORT SCENARIO (HS CODE 30)
- 5.8 KEY CONFERENCES AND EVENTS IN 2026–2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.10 INVESTMENT AND FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS
  - 5.11.1 ZOETIS INC.
  - 5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH
  - 5.11.3 MERCK ANIMAL HEALTH
  - 5.11.4 ELANCO ANIMAL HEALTH
  - 5.11.5 CEVA SANTE ANIMALE
- 5.12 IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET
  - 5.12.1 INTRODUCTION
  - 5.12.2 KEY TARIFF RATES
  - 5.12.3 PRICE IMPACT ANALYSIS
  - 5.12.4 IMPACT ON REGIONS
    - 5.12.4.1 North America
    - 5.12.4.2 Europe
    - 5.12.4.3 Asia Pacific
  - 5.12.5 IMPACT ON END-USE INDUSTRIES
    - 5.12.5.1 Veterinary hospitals & clinics
    - 5.12.5.2 Home care settings
    - 5.12.5.3 Livestock farms
    - 5.12.5.4 Rescue centers & NGOs
    - 5.12.5.5 Other end users

## **6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS**

- 6.1 TECHNOLOGY ANALYSIS
  - 6.1.1 KEY EMERGING TECHNOLOGIES
    - 6.1.1.1 Controlled release formulation
    - 6.1.1.2 Biologics and monoclonal antibodies
  - 6.1.2 COMPLEMENTARY TECHNOLOGIES
    - 6.1.2.1 Digital health and telemedicine platforms
    - 6.1.2.2 Veterinary biomarker analysis
  - 6.1.3 ADJACENT TECHNOLOGIES

6.1.3.1 Wearable animal health monitoring devices

6.1.3.2 Stem cell therapy and regenerative medicine

6.2 TECHNOLOGY/PRODUCT ROADMAP

6.3 PATENT ANALYSIS

6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS

6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015–DECEMBER 2025

6.3.3 LIST OF MAJOR PATENTS, 2023–2025

6.4 FUTURE APPLICATIONS

6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT

6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT

6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK

6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL

6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET

## **7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES**

7.1 REGIONAL REGULATIONS AND COMPLIANCE

7.1.1 REGULATORY FRAMEWORK

7.1.1.1 North America

7.1.1.2 Europe

7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

7.1.3 INDUSTRY STANDARDS

7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products)

7.1.3.2 Good Manufacturing Practice (GMP) Standards – PIC/S Guide (PE 009 series)

7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 – Maximum Residue Limits)

7.2 SUSTAINABILITY INITIATIVES

7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET

7.2.1.1 Virbac – Eco-pack to reduce single-use plastic in veterinary products

7.2.1.2 Boehringer Ingelheim Animal Health – Renewable energy-powered manufacturing

7.2.1.3 Boehringer Ingelheim – Recyclable veterinary delivery device (Aservo, EquiHaler)

### 7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS

## **8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR**

### 8.1 DECISION-MAKING PROCESS

### 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA

#### 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS

#### 8.2.2 BUYING CRITERIA

### 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES

### 8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS

### 8.5 MARKET PROFITABILITY

#### 8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION

#### 8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING

#### 8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY

## **9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE**

### 9.1 INTRODUCTION

#### 9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

### 9.2 DRUGS

#### 9.2.1 ANTI-BACTERIAL DRUGS

9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth

#### 9.2.2 ANTI-FUNGAL DRUGS

9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment

#### 9.2.3 ANTI-VIRAL DRUGS

9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies

#### 9.2.4 ANTI-INFLAMMATORY DRUGS

9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share

#### 9.2.5 ANTI-PARASITIC DRUGS

9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory

#### 9.2.6 ANTI-CANCER DRUGS

9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth

from small base

#### 9.2.7 CARDIOVASCULAR AND RENAL DRUGS

9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share

#### 9.2.8 GASTROINTESTINAL DRUGS

9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand

#### 9.2.9 OTHER DRUGS

### 9.3 MONOCLONAL ANTIBODIES

9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND

### 9.4 IMMUNOMODULATORS

9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE

### 9.5 MEDICATED FEED ADDITIVES

#### 9.5.1 AMINO ACIDS

9.5.1.1 Protein optimization and feed cost efficiency to drive demand

#### 9.5.2 ENZYMES

9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption

#### 9.5.3 VITAMINS AND MINERALS

9.5.3.1 Essential micronutrient supplementation ensures largest market share

#### 9.5.4 OTHER MEDICATED FEED ADDITIVES

## **10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION**

### 10.1 INTRODUCTION

#### 10.2 ORAL

10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS

#### 10.3 PARENTERAL

10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS

#### 10.4 TOPICAL

10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS

#### 10.5 OTHER ROUTES OF ADMINISTRATION

## **11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE**

### 11.1 INTRODUCTION

#### 11.2 SOLID

11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS

#### 11.3 LIQUID

11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS

#### 11.4 SEMI-SOLID

11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE

#### 11.5 AEROSOL/SPRAY

11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK

#### 11.6 PREMIX FORMULATIONS

11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET

## **12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION**

### 12.1 INTRODUCTION

#### 12.2 INFECTIOUS DISEASES

12.2.1 ZONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET

#### 12.3 DERMATOLOGICAL DISEASES

12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET

#### 12.4 PAIN MANAGEMENT

12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET

#### 12.5 CARDIOVASCULAR AND RENAL DISEASES

12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET

#### 12.6 GASTROINTESTINAL DISEASES

12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET

#### 12.7 OTHER INDICATIONS

## **13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE**

### 13.1 INTRODUCTION

### 13.2 COMPANION ANIMALS

#### 13.2.1 DOGS

13.2.1.1 Increasing population and adoption of dogs to drive market

#### 13.2.2 CATS

13.2.2.1 Emerging trends in feline pharmaceuticals to boost market

#### 13.2.3 HORSES

13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products

#### 13.2.4 OTHER COMPANION ANIMALS

### 13.3 LIVESTOCK ANIMALS

#### 13.3.1 CATTLE

13.3.1.1 Economic importance of dairy and beef cattle to drive growth

#### 13.3.2 SWINE

13.3.2.1 Growing surgical volume for acute conditions in swine to drive market

#### 13.3.3 POULTRY

13.3.3.1 Growing focus on infection prevention and flock health management to drive market

#### 13.3.4 OTHER LIVESTOCK ANIMALS

## **14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL**

### 14.1 INTRODUCTION

### 14.2 VETERINARY HOSPITAL PHARMACIES

14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET

### 14.3 RETAIL PHARMACIES

14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS

### 14.4 ONLINE PHARMACIES

14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH

### 14.5 DIRECT SALES

14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS

## **15 VETERINARY PHARMACEUTICALS MARKET, BY END USER**

## 15.1 INTRODUCTION

## 15.2 VETERINARY HOSPITALS & CLINICS

### 15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS

## 15.3 LIVESTOCK FARMS

### 15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE

## 15.4 HOME CARE SETTINGS

### 15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH

## 15.5 OTHER END USERS

# 16 VETERINARY PHARMACEUTICALS MARKET, BY REGION

## 16.1 INTRODUCTION

## 16.2 NORTH AMERICA

### 16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

### 16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

#### 16.2.3 US

##### 16.2.3.1 Surge in animal healthcare expenditure to boost market

#### 16.2.4 CANADA

##### 16.2.4.1 Growing pet population and advanced veterinary services to drive market

## 16.3 EUROPE

### 16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

### 16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

#### 16.3.3 GERMANY

##### 16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products

#### 16.3.4 UK

##### 16.3.4.1 Increasing pet ownership to propel market

#### 16.3.5 FRANCE

##### 16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players

#### 16.3.6 ITALY

##### 16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market

#### 16.3.7 SPAIN

##### 16.3.7.1 Increasing awareness of animal health to drive market

- 16.3.8 REST OF EUROPE
- 16.4 ASIA PACIFIC
  - 16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  - 16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
  - 16.4.3 JAPAN
    - 16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market
  - 16.4.4 CHINA
    - 16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market
  - 16.4.5 INDIA
    - 16.4.5.1 Increasing livestock population to propel market growth
  - 16.4.6 AUSTRALIA
    - 16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth
  - 16.4.7 SOUTH KOREA
    - 16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth
  - 16.4.8 PHILIPPINES
    - 16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market
  - 16.4.9 REST OF ASIA PACIFIC
- 16.5 LATIN AMERICA
  - 16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  - 16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
  - 16.5.3 BRAZIL
    - 16.5.3.1 Growing pet population and rising disposable incomes to drive market
  - 16.5.4 MEXICO
    - 16.5.4.1 Robust livestock base and growing companion animal care to drive market
  - 16.5.5 REST OF LATIN AMERICA
- 16.6 MIDDLE EAST & AFRICA
  - 16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  - 16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
- 16.7 GCC COUNTRIES
  - 16.7.1 KINGDOM OF SAUDI ARABIA (KSA)
    - 16.7.1.1 Vision 2030 investments to drive market
  - 16.7.2 UNITED ARAB EMIRATES (UAE)

16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth

16.7.3 REST OF GCC COUNTRIES

16.7.4 REST OF MIDDLE EAST & AFRICA

## **17 COMPETITIVE LANDSCAPE**

### **17.1 INTRODUCTION**

17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026

### **17.2 REVENUE ANALYSIS, 2023–2025**

### **17.3 MARKET SHARE ANALYSIS, 2025**

17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025

17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025

### **17.4 PRODUCT/BRAND COMPARISON**

### **17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025**

17.5.1 STARS

17.5.2 EMERGING LEADERS

17.5.3 PERVASIVE PLAYERS

17.5.4 PARTICIPANTS

17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025

17.5.5.1 Company footprint

17.5.5.2 Region footprint

17.5.5.3 Product type footprint

17.5.5.4 Route of administration footprint

17.5.5.5 Indication footprint

17.5.5.6 End user footprint

### **17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025**

17.6.1 PROGRESSIVE COMPANIES

17.6.2 RESPONSIVE COMPANIES

17.6.3 DYNAMIC COMPANIES

17.6.4 STARTING BLOCKS

17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025

17.6.5.1 Detailed list of key startups/SMEs

17.6.5.2 Competitive benchmarking of key startups/SMEs

### **17.7 COMPANY VALUATION AND FINANCIAL METRICS**

### **17.8 COMPETITIVE SCENARIO**

17.8.1 PRODUCT LAUNCHES & APPROVALS

17.8.2 DEALS

17.8.3 EXPANSIONS

17.8.4 OTHER DEVELOPMENTS

## **18 COMPANY PROFILES**

### **18.1 KEY PLAYERS**

#### **18.1.1 ZOETIS INC.**

18.1.1.1 Business overview

18.1.1.2 Products offered

18.1.1.3 Recent developments

18.1.1.3.1 Product launches & approvals

18.1.1.3.2 Expansions

18.1.1.3.3 Other developments

18.1.1.4 MnM view

18.1.1.4.1 Right to win

18.1.1.4.2 Strategic choices

18.1.1.4.3 Weaknesses and competitive threats

#### **18.1.2 MERCK & CO., INC**

18.1.2.1 Business overview

18.1.2.2 Products offered

18.1.2.3 Recent developments

18.1.2.3.1 Product launches & approvals

18.1.2.3.2 Deals

18.1.2.3.3 Expansions

18.1.2.4 MnM view

18.1.2.4.1 Right to win

18.1.2.4.2 Strategic choices

18.1.2.4.3 Weaknesses and competitive threats

#### **18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH**

18.1.3.1 Business overview

18.1.3.2 Products offered

18.1.3.3 Recent developments

18.1.3.3.1 Product launches & approvals

18.1.3.3.2 Deals

18.1.3.3.3 Expansions

18.1.3.4 MnM view

18.1.3.4.1 Right to win

18.1.3.4.2 Strategic choices

18.1.3.4.3 Weaknesses and competitive threats

#### 18.1.4 ELANCO ANIMAL HEALTH INCORPORATED

- 18.1.4.1 Business overview
- 18.1.4.2 Products offered
- 18.1.4.3 Recent developments
  - 18.1.4.3.1 Product launches & approvals
  - 18.1.4.3.2 Expansions
  - 18.1.4.3.3 Other developments
- 18.1.4.4 MnM view
  - 18.1.4.4.1 Right to win
  - 18.1.4.4.2 Strategic choices
  - 18.1.4.4.3 Weaknesses and competitive threats

#### 18.1.5 VIRBAC

- 18.1.5.1 Business overview
- 18.1.5.2 Products offered
- 18.1.5.3 Recent developments
  - 18.1.5.3.1 Product launches & approvals
  - 18.1.5.3.2 Deal
  - 18.1.5.3.3 Expansions
- 18.1.5.4 MnM view
  - 18.1.5.4.1 Right to win
  - 18.1.5.4.2 Strategic choices
  - 18.1.5.4.3 Weaknesses and competitive threats

#### 18.1.6 CEVA

- 18.1.6.1 Business overview
- 18.1.6.2 Products offered
- 18.1.6.3 Recent developments
  - 18.1.6.3.1 Deals
  - 18.1.6.3.2 Expansions

#### 18.1.7 VETOQUINOL

- 18.1.7.1 Business overview
- 18.1.7.2 Products offered
- 18.1.7.3 Recent developments
  - 18.1.7.3.1 Product launches & approvals
  - 18.1.7.3.2 Deals

#### 18.1.8 DECHRA PHARMACEUTICALS PLC

- 18.1.8.1 Business overview
- 18.1.8.2 Products offered
- 18.1.8.3 Recent developments
  - 18.1.8.3.1 Product launches & approvals

- 18.1.8.3.2 Deals
- 18.1.8.3.3 Other developments
- 18.1.9 NORBROOK
  - 18.1.9.1 Business overview
  - 18.1.9.2 Products offered
  - 18.1.9.3 Recent developments
    - 18.1.9.3.1 Product launches & approvals
    - 18.1.9.3.2 Deals
    - 18.1.9.3.3 Expansions
    - 18.1.9.3.4 Other developments
- 18.1.10 BIMEDA CORPORATE
  - 18.1.10.1 Business overview
  - 18.1.10.2 Products offered
  - 18.1.10.3 Recent developments
    - 18.1.10.3.1 Product launches & approvals
    - 18.1.10.3.2 Deals
    - 18.1.10.3.3 Expansions
- 18.1.11 HESTER BIOSCIENCES LIMITED
  - 18.1.11.1 Business overview
  - 18.1.11.2 Products offered
- 18.1.12 INDIAN IMMUNOLOGICALS LTD.
  - 18.1.12.1 Business overview
  - 18.1.12.2 Products offered
- 18.1.13 ANIMALCARE GROUP PLC
  - 18.1.13.1 Business overview
  - 18.1.13.2 Products offered
  - 18.1.13.3 Recent developments
    - 18.1.13.3.1 Deals
    - 18.1.13.3.2 Product launches & approvals
- 18.1.14 KYORITSU SEIYAKU CORPORATION
  - 18.1.14.1 Business overview
  - 18.1.14.2 Products offered
  - 18.1.14.3 Recent developments
    - 18.1.14.3.1 Product launches & approvals
    - 18.1.14.3.2 Deals
- 18.1.15 CALIER
  - 18.1.15.1 Business overview
  - 18.1.15.2 Products offered
  - 18.1.15.3 Recent developments

18.1.15.3.1 Product launches & approvals

## 18.2 OTHER PLAYERS

18.2.1 DOPHARMA

18.2.2 PHARMGATE ANIMAL HEALTH

18.2.3 BIOVETA, A.S.

18.2.4 NEXTMUNE

18.2.5 TRIVIUMVET

18.2.6 DOMES PHARMA

18.2.7 UNIVET LIMITED

18.2.8 CENAVISA, S.L.

18.2.9 FATRO S.P.A.

18.2.10 CHANELLE PHARMA

## 19 RESEARCH METHODOLOGY

### 19.1 RESEARCH DATA

#### 19.1.1 SECONDARY DATA

19.1.1.1 Key data from secondary sources

#### 19.1.2 PRIMARY DATA

19.1.2.1 Key data from primary sources

19.1.2.2 Key industry insights

19.1.2.3 Key industry insights

### 19.2 MARKET SIZE ESTIMATION

### 19.3 GROWTH FORECAST

#### 19.3.1 KEY INDUSTRY INSIGHTS

### 19.4 MARKET BREAKDOWN AND DATA TRIANGULATION

### 19.5 RESEARCH ASSUMPTIONS

### 19.6 RESEARCH LIMITATIONS

### 19.7 RISK ASSESSMENT

## 20 APPENDIX

### 20.1 DISCUSSION GUIDE

### 20.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

### 20.3 CUSTOMIZATION OPTIONS

#### 20.3.1 PRODUCT ANALYSIS

#### 20.3.2 US END USER ANALYSIS

#### 20.3.3 GEOGRAPHIC ANALYSIS

#### 20.3.4 COMPANY INFORMATION

- 20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
- 20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE
- 20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
- 20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
- 20.4 RELATED REPORTS
- 20.5 AUTHOR DETAILS

## List Of Tables

### LIST OF TABLES

- TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
- TABLE 2 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024
- TABLE 3 COMPANION ANIMAL POPULATION STATISTICS, BY REGION
- TABLE 4 RECENT GOVERNMENT-REPORTED INDICATORS
- TABLE 5 TRENDS IN CONSUMPTION OF MEAT & MILK IN DEVELOPED & EMERGING ECONOMIES
- TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
- TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
- TABLE 8 UNMET CUSTOMER NEEDS AND WHITE SPACES IN VETERINARY PHARMACEUTICALS MARKET.
- TABLE 9 INTERCONNECTED MARKETS IN VETERINARY PHARMACEUTICALS MARKET
- TABLE 10 CROSS-SECTOR MARKETS IN VETERINARY PHARMACEUTICALS MARKET
- TABLE 11 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
- TABLE 12 IMPACT OF PORTER'S FIVE FORCES ON VETERINARY PHARMACEUTICALS MARKET
- TABLE 13 GDP TREND AND FORECAST, BY COUNTRY, 2021–2030 (USD BILLION)
- TABLE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025
- TABLE 15 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025
- TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025
- TABLE 17 IMPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION)
- TABLE 18 EXPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION)
- TABLE 19 DETAILED LIST OF CONFERENCES AND EVENTS, 2026–2027
- TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES
- TABLE 21 TECHNOLOGY/PRODUCT ROADMAP
- TABLE 22 VETERINARY PHARMACEUTICALS MARKET: LIST OF MAJOR PATENTS, JANUARY 2023–DECEMBER 2025
- TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS

TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS

TABLE 28 KEY BUYING CRITERIA FOR TOP THREE END USERS

TABLE 29 VETERINARY PHARMACEUTICALS MARKET: UNMET NEEDS IN KEY END-USE SETTINGS

TABLE 30 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

TABLE 31 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 32 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 33 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 34 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-BACTERIAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 35 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-FUNGAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 36 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-VIRAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 37 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 38 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-PARASITIC DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 39 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-CANCER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 40 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 41 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 42 VETERINARY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 43 VETERINARY PHARMACEUTICALS MARKET FOR MONOCLONAL

ANTIBODIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 44 VETERINARY PHARMACEUTICALS MARKET FOR

IMMUNOMODULATORS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 45 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED  
ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 46 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED  
ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 47 VETERINARY PHARMACEUTICALS MARKET FOR AMINO ACIDS, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 48 VETERINARY PHARMACEUTICALS MARKET FOR ENZYMES, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 49 VETERINARY PHARMACEUTICALS MARKET FOR VITAMINS AND  
MINERALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 50 VETERINARY PHARMACEUTICALS MARKET FOR OTHER MEDICATED  
FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 51 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF  
ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 52 VETERINARY PHARMACEUTICALS MARKET FOR ORAL, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 53 VETERINARY PHARMACEUTICALS MARKET FOR PARENTERAL, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 54 VETERINARY PHARMACEUTICALS MARKET FOR TOPICAL, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 55 VETERINARY PHARMACEUTICALS MARKET FOR OTHER ROUTES OF  
ADMINISTRATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 56 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,  
2024–2031 (USD MILLION)

TABLE 57 VETERINARY PHARMACEUTICALS MARKET FOR SOLID, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 58 VETERINARY PHARMACEUTICALS MARKET FOR LIQUID, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 59 VETERINARY PHARMACEUTICALS MARKET FOR SEMI-SOLID, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 60 VETERINARY PHARMACEUTICALS MARKET FOR AEROSOL/SPRAY, BY  
COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 61 VETERINARY PHARMACEUTICALS MARKET FOR PREMIX  
FORMULATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 62 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,  
2024–2031 (USD MILLION)

TABLE 63 VETERINARY PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 64 VETERINARY PHARMACEUTICALS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 65 VETERINARY PHARMACEUTICALS MARKET FOR PAIN MANAGEMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 66 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 67 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 68 VETERINARY PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 69 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 70 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 71 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 72 VETERINARY PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 73 VETERINARY PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 74 VETERINARY PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 75 VETERINARY PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 76 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 77 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 78 VETERINARY PHARMACEUTICALS MARKET FOR CATTLE, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)

TABLE 79 VETERINARY PHARMACEUTICALS MARKET FOR SWINE, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 80 VETERINARY PHARMACEUTICALS MARKET FOR POULTRY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 81 VETERINARY PHARMACEUTICALS MARKET FOR OTHER LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 82 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION

CHANNEL, 2024–2031 (USD MILLION)

TABLE 83 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITAL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 84 VETERINARY PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 85 VETERINARY PHARMACEUTICALS MARKET FOR ONLINE PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 86 VETERINARY PHARMACEUTICALS MARKET FOR DIRECT SALES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 87 VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 88 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 89 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK FARMS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 90 VETERINARY PHARMACEUTICALS MARKET FOR HOME CARE SETTINGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 91 VETERINARY PHARMACEUTICALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 92 VETERINARY PHARMACEUTICALS MARKET, BY REGION, 2024–2031 (USD MILLION)

TABLE 93 VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)

TABLE 94 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 95 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 96 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

TABLE 97 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 98 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 99 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 100 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 101 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 102 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 103 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 104 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 105 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 106 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 107 US: KEY MACRO INDICATORS

TABLE 108 US: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 109 US: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 110 US: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 111 US: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 112 US: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 113 US: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 114 US: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 115 US: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 116 US: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 117 US: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 118 US: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 119 CANADA: KEY MACRO INDICATORS

TABLE 120 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 121 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 122 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR

MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 123 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 124 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 125 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 126 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 127 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 128 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 129 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 130 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 131 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 132 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 133 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

TABLE 134 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 135 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 136 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 137 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 138 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 139 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 140 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 141 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 142 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 143 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 144 GERMANY: KEY MACRO INDICATORS

TABLE 145 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 146 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 147 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 148 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 149 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 150 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 151 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 152 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 153 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 154 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 155 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 156 UK: KEY MACRO INDICATORS

TABLE 157 UK: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 158 UK: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 159 UK: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 160 UK: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 161 UK: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 162 UK: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,

2024–2031 (USD MILLION)

TABLE 163 UK: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 164 UK: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 165 UK: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 166 UK: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 167 UK: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 168 FRANCE: KEY MACRO INDICATORS

TABLE 169 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 170 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 171 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 172 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 173 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 174 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 175 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 176 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 177 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 178 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 179 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 180 ITALY: KEY MACRO INDICATORS

TABLE 181 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 182 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 183 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 184 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 185 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 186 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 187 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 188 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 189 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 190 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 191 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 192 SPAIN: KEY MACRO INDICATORS

TABLE 193 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 194 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 195 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 196 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 197 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 198 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 199 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 200 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 201 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 202 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 203 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 204 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 205 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 206 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 207 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 208 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 209 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 210 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 211 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 212 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 213 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 214 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 215 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)

TABLE 216 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 217 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)

TABLE 218 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 219 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 220 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 221 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 222 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY

INDICATION, 2024–2031 (USD MILLION)

TABLE 223 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 224 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 225 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 226 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 227 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

TABLE 228 JAPAN: KEY MACRO INDICATORS

TABLE 229 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)

TABLE 230 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 231 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)

TABLE 232 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)

TABLE 233 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)

TABLE 234 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)

TABLE 235 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)

TABLE 236 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 237 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)

TABLE 238 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)

TABLE 239 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)

## List Of Figures

### LIST OF FIGURES

FIGURE 1 VETERINARY PHARMACEUTICALS MARKET SEGMENTATION

FIGURE 2 MARKET SCENARIO

FIGURE 3 VETERINARY PHARMACEUTICALS MARKET, 2024–2031

FIGURE 4 VETERINARY PHARMACEUTICALS MARKET: MAJOR STRATEGIES ADOPTED BY KEY PLAYERS, 2022–2025

FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY PHARMACEUTICALS MARKET

FIGURE 6 VETERINARY PHARMACEUTICALS MARKET: HIGH-GROWTH SEGMENTS, 2026–2031

FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 8 INCREASING PET CARE EXPENDITURE TO DRIVE MARKET

FIGURE 9 DRUGS SEGMENT AND CHINA DOMINATED MARKET IN 2025

FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

FIGURE 11 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

FIGURE 12 VETERINARY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 13 PET POPULATION IN MAJOR MARKETS, 2022 (MILLION)

FIGURE 14 EUROPE: PET POPULATION, 2021–2023

FIGURE 15 VETERINARY PHARMACEUTICALS MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 16 VETERINARY PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS

FIGURE 17 VETERINARY PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 18 VETERINARY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS

FIGURE 19 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS

FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN VETERINARY PHARMACEUTICALS MARKET, 2021–2025

FIGURE 21 PATENTS APPLIED AND GRANTED, JANUARY 2015–DECEMBER 2025

FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PHARMACEUTICALS PRODUCTS, JANUARY 2015–DECEMBER 2025

FIGURE 23 VETERINARY PHARMACEUTICALS MARKET: DECISION-MAKING FACTORS

FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR

**VETERINARY PHARMACEUTICAL PRODUCTS**

FIGURE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS

FIGURE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES

FIGURE 27 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC  
SNAPSHOTFIGURE 28 NORTH AMERICA: EXPECTED GROWTH IN NUMBER OF  
VETERINARIANS, 2020–2030

FIGURE 29 NORTH AMERICA: PET POPULATION, 2024 (MILLION)

FIGURE 30 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET  
SNAPSHOT

FIGURE 31 US: TOTAL PET HEALTH EXPENDITURE, 2020–2024

FIGURE 32 EUROPE: PET POPULATION, 2023 (MILLION)

FIGURE 33 ASIA PACIFIC: DOG POPULATION, BY COUNTRY, 2024

FIGURE 34 ASIA PACIFIC: CAT POPULATION, BY COUNTRY, 2024

FIGURE 35 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET  
SNAPSHOTFIGURE 36 VETERINARY PHARMACEUTICALS MARKET: REVENUE ANALYSIS OF  
KEY PLAYERS, 2023?2025

FIGURE 37 VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025

FIGURE 38 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS,  
2025FIGURE 39 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE  
ANALYSIS, 2025

FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 41 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION  
MATRIX (KEY PLAYERS), 2025

FIGURE 42 VETERINARY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT

FIGURE 43 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION  
MATRIX (STARTUPS/SMES), 2025

FIGURE 44 EV/EBITDA OF KEY VENDORS

FIGURE 45 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 46 ZOETIS INC.: COMPANY SNAPSHOT (2025)

FIGURE 47 MERCK &amp; CO., INC.: COMPANY SNAPSHOT (2025)

FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY  
SNAPSHOT (2025)FIGURE 49 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT  
(2025)

FIGURE 50 VIRBAC: COMPANY SNAPSHOT (2025)

FIGURE 51 CEVA: COMPANY SNAPSHOT (2025)

FIGURE 52 VETOQUINOL: COMPANY SNAPSHOT (2025)  
FIGURE 53 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2025)  
FIGURE 54 INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT (2025)  
FIGURE 55 ANIMALCARE GROUP PLC: COMPANY SNAPSHOT  
FIGURE 56 RESEARCH DESIGN  
FIGURE 57 PRIMARY SOURCES  
FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS  
FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS  
FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS  
FIGURE 61 MARKET SIZE ESTIMATION APPROACH: REVENUE SHARE ANALYSIS  
FIGURE 62 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025)  
FIGURE 63 VETERINARY PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS  
FIGURE 64 TOP-DOWN APPROACH  
FIGURE 65 VETERINARY PHARMACEUTICALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031)  
FIGURE 66 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF VETERINARY PHARMACEUTICALS MARKET (2026-2031)  
FIGURE 67 DATA TRIANGULATION

## I would like to order

Product name: Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User-Global Forecast to 2031

Product link: <https://marketpublishers.com/r/VF7A24B4FAA7EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VF7A24B4FAA7EN.html>